Spironolactone for rheumatoid arthritis with active symptoms
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests whether spironolactone can reduce symptoms and inflammation in people with rheumatoid arthritis that is still active despite standard arthritis medicines. You may be able to join if your rheumatoid arthritis remains active and your current treatment plan has been stable for at least several months.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have rheumatoid arthritis (RA) diagnosed using accepted RA criteria.
- Your RA is currently active, based on a specific score (DAS28-CRP 3.2 or higher).
- Your RA medicines have been stable for at least 12 weeks, and they have not controlled your disease well enough.
- If you take steroid tablets, the dose must have been stable for at least 4 weeks.
- You can sign informed consent and understand the study after a preliminary visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called SR-878 for people with rheumatoid arthritis. It aims to see if the drug is safe and tolerable. You may join if you are between 18 and 60, have RA for at least 3 months, and take a stable dose of methotrexate.
This study tests a new medication called AZD1163 for people with rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if the drug can safely reduce joint swelling and pain.
This study tests whether an anti-inflammatory diet can help people with rheumatoid arthritis by lowering inflammation and disease activity. You may join if your symptoms are currently mild to moderate and you haven’t recently changed medications or your treatment plan.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
This study tests a new oral medication, PTC844, for people with active rheumatoid arthritis whose current treatments have not worked well enough or who haven't tried any yet. The goal is to see if it can reduce joint pain and swelling.
This trial tests a new experimental antibody called GNC-038 for people with moderate to severe rheumatoid arthritis (RA) that hasn't responded well enough to standard treatments. It aims to see if targeting specific immune cells can reduce inflammation and improve symptoms.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.